TPI 1020
Asset
Nitric oxide-donating derivative of budesonide with anti-inflammatory activity
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- NR3C1
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Copd bronchitis
Phase 2, Completed, NCT00483743, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Trials1
- Evidence for its targets2
- Competitors7
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026, 1 source